Integrated BioTherapeutics Inc

Integrated BioTherapeutics Inc (IBT) is a research-based company headquartered in Gaithersburg, Maryland. The company employs 45 people and generates $50 million in annual revenue. IBT is dedicated to the development of vaccines and biotherapeutic molecules targeting emerging infectious agents. IBT focuses its research on Ebola and Marburg viral hemorrhagic fevers and staph aureus. The company is currently developing a panfilovirus vaccine under a contract with the National Institute of Allergy and Infectious Diseases (NIAID). Additionally, IBT is conducting phase I trials for an SEB vaccine sponsored by the National Institutes of Health (NIH). IBT has established close collaborations with various United States government agencies, including the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Cancer Institute (NCI), the NIH, and the Department of Defense (DOD). IBT also operates IBT Bioservices, a contract research and development services business. IBT Bioservices develops screening assays and disease models to identify antiviral and antibacterial compounds and therapeutics for client companies. They also offer contract testing services utilizing the Mesoscale Discovery platform by MSD. For more information about IBT Bioservices, visit www.ibtbioservices.com.